METHODS	A total of 1176 healthy postmenopausal women age 45 years and older without evidence of endometrial abnormalities were randomly assigned to receive either unopposed E2 1 mg , or continuous-combined formulations of E2 1 mg and norethindrone acetate 0.1 mg , 0.25 mg , or 0.5 mg .\